nystatin-a1 and Respiratory-Tract-Diseases

Antifungal therapy has been claimed to be effective in polysymptomatic patients with diffuse symptoms from multiple body systems and even well defined diseases, traditionally not related to fungi. Hypersensitivity to fungus proteins and mycotoxins has been proposed as the cause.. We conducted a 4-week randomized, double-blind, placebo-controlled study in 116 individuals selected by a 7-item questionnaire to determine whether the antifungal agent nystatin given orally was superior to placebo. At the onset of the study, the patients were free to select either their regular diet or a sugar- and yeast-free diet, which resulted in four different subgroups: nystatin + diet (ND); placebo + diet (PD); nystatin (N); and placebo (P).. Nystatin was significantly better than placebo in reduction of the overall symptom score (P < 0.003). In six of the 45 individually recorded symptoms, the improvement was significant (P < 0.01). All three active treatment groups reduced their overall symptom scores significantly (P < 0.0001), while the placebo regimen had no effect (P = 0.83). The benefit of diet was significant within both the nystatin (ND > N) and the placebo groups (PD > P).. Nystatin is superior to placebo in reducing localized and systemic symptoms in individuals with presumed fungus hypersensitivity as selected by a 7-item questionnaire. This superiority is probably enhanced even further by a sugar- and yeast-free diet.

Topics: Adult; Aged; Analysis of Variance; Antifungal Agents; Dietary Sucrose; Double-Blind Method; Family Practice; Fatigue; Female; Female Urogenital Diseases; Gastrointestinal Diseases; Humans; Male; Male Urogenital Diseases; Medical History Taking; Memory Disorders; Middle Aged; Multiple Carboxylase Deficiency; Mycoses; Nystatin; Pain; Respiratory Tract Diseases; Skin Diseases; Surveys and Questionnaires; Treatment Outcome

Fifty consecutive patients with respiratory diseases who developed oropharyngeal candidiasis were assessed clinically and microbiologically before and after seven days' treatment with nystatin suspension or pastilles (a new formulation). In 45 patients in whom microbiology yielded positive results there was frequent associated use of oral corticosteroids, antibiotics, sedatives, and inhaled corticosteroid, while in a few patients atropine analogues may have predisposed to infection. Dentures were worn by 32 of the infected patients. Concomitant treatment of dentures in chronically infected patients appeared to improve the therapeutic response. Pastilles and suspension were equally efficacious both clinically and microbiologically. The potential for enhanced drug delivery to the oropharynx suggests that nystatin pastilles may be useful in patients in whom poor compliance seems likely.

Topics: Administration, Oral; Adolescent; Adult; Aged; Anti-Bacterial Agents; Candidiasis, Oral; Dentures; Female; Humans; Male; Middle Aged; Nystatin; Respiratory Tract Diseases; Respiratory Tract Neoplasms; Steroids; Tablets

Topics: Adolescent; Adult; Aged; Animals; Candida; Candidiasis; Female; Humans; Male; Middle Aged; Nystatin; Respiratory Tract Diseases; Tetracycline

Topics: Adolescent; Adult; Aged; Candida; Child; Child, Preschool; Female; Humans; Infant; Klebsiella; Male; Microbial Sensitivity Tests; Middle Aged; Nystatin; Respiratory Tract Diseases; Respiratory Tract Infections; Sputum; Staphylococcus

Topics: Candidiasis; Child; Chronic Disease; Diagnosis, Differential; Esophagitis; Fluoroscopy; Geriatrics; Humans; Nystatin; Respiratory Tract Diseases